- Datamonitor Healthcare estimates that in 2018 there were approximately 1.5 billion prevalent cases of dyslipidemia in adults aged 20 years and older worldwide, and forecasts that number to increase to 1.7 billion prevalent cases by 2027.
- The dyslipidemia market is well established and the branded segment has seen declining sales due to generics. However, the market is poised to resume steady growth due to the introduction of novel agents, improved access with price competition, and new cardiovascular outcomes data with label expansions.
- In the hypercholesterolemia segment, the injectable PCSK9 inhibitors have struggled due to payer restrictions, but declining net pricing in the US is hoped to improve access and spur growth, though this will depend on the extent to which payers retain prior authorization. Price competition may increase with the introduction of siRNA inclisiran, but Novartis also plans to use inclisiran’s more convenient maintenance dosing of every six months to pursue administration in healthcare provider offices, with medical rather than pharmacy benefit coverage, including Medicare Part B, to improve access. Inclisiran’s cardiovascular outcomes trial (CVOT) is also designed to show a numerically stronger topline benefit.
- Oral bempedoic acid will be limited by modest low-density lipoprotein cholesterol (LDL-C) lowering, particularly on top of statins, but good efficacy with its fixed-dose combination with ezetimibe in statin-intolerant patients will be an important addition to that high-need segment. In addition, its oral route could lead it to be preferred initially in patients failing statins +/- ezetimibe who are not too far from goal, depending on the risk of the patient and whether the particular physician feels that reaching certain LDL-C targets is acceptable rather than driving it as low as possible. Given the large number of hypercholesterolemia patients not meeting goal, either with or without statin intolerance, if bempedoic acid’s CVOT is positive, it should still be fairly successful despite its modest efficacy.
- In the hypertriglyceridemia segment (including mixed dyslipidemia), positive CVOT data for the omega-3 fatty acid (FA) Vascepa, a formulation of EPA, has already started to drive substantial growth, but while the FDA is sure to grant it a label expansion for secondary prevention, it is unclear what type of primary prevention patients the FDA will include in the indication. The drug’s prospects also largely depend on whether Epanova, a mixture of DHA and EPA, likewise has a positive CVOT. Epanova is likely to lag behind Vascepa if results are numerically not as strong, though it could benefit from AstraZeneca’s stronger primary care presence. Depending on the details, Epanova’s CVOT could also give physicians more confidence in generics of DHA/EPA when used in a high enough dose, though sponsors of other branded formulations, like CaPre, are hoping that would lead some to prefer their own formulations for other features. Vascepa’s success could revive interest in triglycerides as a broader target, though its CV benefit may involve a number of other effects as well.
- While fibrates have mixed CVOT data and failed to show a benefit in combination with statins in ACCORD, if the PROMINENT trial of pemafibrate is positive, it could bolster subgroup analyses of ACCORD, suggesting a benefit in patients with high triglycerides and low HDL-C. This would increase competition for omega-3 FAs.
- In the orphan drug segment, anti-ANGPTL3 monoclonal antibody evinacumab is expected to take share from oral Juxtapid in homozygous familial hypercholesterolemia (HoFH), due to safety and tolerability issues with the latter, but will still be limited by competition with lower-priced PCSK9 inhibitors in eligible patients, assuming evinacumab has orphan pricing. Evinacumab’s HoFH trial also involved inconvenient IV dosing, but subcutaneous dosing is being studied in a Phase II trial in patients with persistent hypercholesterolemia, despite treatment even with PCSK9 inhibitors, and the drug additionally lowers triglycerides, so it could expand to other orphan dyslipidemia indications as well. The antisense drug Waylivra, which targets ApoC-III, may not be approved in the US for familial chylomicronemia syndrome due to safety issues. However, other earlier-stage antisense and RNAi drugs targeting ANGPTL3, ApoC-III, and Apo(a) may avoid these safety issues and have gained large pharma interest, including plans for a CVOT for a broader indication.
- Given limited budgets for many patients, there will be indirect competition between drugs targeting LDL-C and those targeting triglycerides, if patients are eligible for both, as well as with diabetes drugs that have CV and renal benefits.
- In the US, different specialties and primary care physicians may use different dyslipidemia guidelines with varying approaches to lipid targets.
- The overall likelihood of approval of a Phase I dyslipidemia asset is 10.4%, and the average probability a drug advances from Phase III is 65.4%. Dyslipidemia drugs, on average, take 8.1 years from Phase I to approval, compared to 9.8 years in the overall cardiovascular space.
- There have been 15 licensing and asset acquisition deals involving dyslipidemia drugs during 2014–19. A $1,550m licensing agreement signed in 2019 between Pfizer and Akcea for AKCEA-ANGPTL3-LRx was the largest deal, though only $250m was upfront.
Shop
You are here: Home > Shop > Disease analysis > Cardiovascular and Metabolic > Disease Analysis: Dyslipidemia
Disease Analysis: Dyslipidemia
You are here: Home > Shop > Disease analysis > Cardiovascular and Metabolic > Disease Analysis: Dyslipidemia
Disease Analysis: Dyslipidemia
Author: Peter Chang
Publisher: Datamonitor Healthcare
Published:
29 November 2019
Number of pages:
103
Formats:
PDF
Report code:
DMKC0210072
- Description
- Contents
- Enquire
KET TAKEAWAYS
CONTENTS
8 OVERVIEW
8 Latest key takeaways
10 DISEASE BACKGROUND
10 Definition
10 Patient segmentation
11 TREATMENT
11 Treatment guidelines vary across regions
11 Treatment recommendations focus on risk groups
12 Recommendations on specific classes
16 EPIDEMIOLOGY
20 MARKETED DRUGS
27 PIPELINE DRUGS
35 KEY REGULATORY EVENTS
35 Amarin Seeks EU Fast-Track For Potential Cardiovascular Blockbuster
35 YouTube Video Suggesting Livalo Is Safer Than Other Statins Is Dinged By US FDA
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 Novartis To Pay $9.7bn For The Medicines Company
38 Pfizer Reaffirms CV Disease Commitment With Deal For Akcea’s ANGPTL3 Drug
38 Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
38 Asia Deal Watch: Boost For Esperion’s Cholesterol Candidate As Daiichi Brought On Board
39 Novo Carves Deeper Niche Into CV Market With Staten Dyslipidemia Investment
40 CLINICAL TRIAL LANDSCAPE
41 Sponsors by status
42 Sponsors by phase
43 Recent events
45 DRUG ASSESSMENT MODEL
45 Cholesterol-lowering drugs
47 Triglyceride-lowering drugs
47 Lipid-lowering and CVOT efficacy data
54 MARKET DYNAMICS
59 FUTURE TRENDS
59 New launches and CVOT data will drive growth in the dyslipidemia market over the forecast period
59 Competition among the PCSK9 inhibitors will need to lower net prices more for the class to succeed
60 Price pressures and affordability will continue to be major factors limiting growth
61 CONSENSUS FORECASTS
64 RECENT EVENTS AND ANALYST OPINION
64 Inclisiran for Dyslipidemia (November 16 & 18, 2019)
67 Vascepa for Dyslipidemia (November 18, 2019)
69 Vascepa for Dyslipidemia (November 14, 2019)
71 Vascepa for Dyslipidemia (November 12, 2019)
73 ARO-ANG3 for Dyslipidemia and ARO-APOC3 for Lipoprotein Lipase Deficiency (September 16, 2019)
76 Inclisiran for Dyslipidemia (September 2, 2019)
78 ETC-1002/Ezetimibe FDC for Dyslipidemia (August 29, 2019)
80 Inclisiran for Dyslipidemia (August 26, 2019)
82 Evinacumab for Dyslipidemia (August 14, 2019)
83 Vascepa for Dyslipidemia (August 8, 2019)
85 Inclisiran for Dyslipidemia (May 18, 2019)
87 ETC-1002 for Dyslipidemia (May 5, 2019)
88 ETC-1002 for Dyslipidemia (March 13, 2019)
89 CER-001 for Dyslipidemia (December 5, 2018)
90 Vascepa for Dyslipidemia (November 10, 2018)
96 KEY UPCOMING EVENTS
97 KEY OPINION LEADER INSIGHTS
97 Interviews with physicians at the ADA conference regarding Vascepa
97 Interview regarding PCSK9 reimbursement with a KOL from a large US payer
99 UNMET NEEDS
99 Improved options for statin-intolerant patients
99 A well-tolerated oral drug with LDL-C lowering as good as the current injectable PCSK9 inhibitors when added to a statin
99 Addressing the residual risk remaining in higher-risk patients despite well-controlled LDL-C levels
99 A way to motivate patients to stick with treatment if their lipid levels are elevated
100 BIBLIOGRAPHY
101 Prescription information
102 APPENDIX
LIST OF FIGURES
12 Figure 1: Hypercholesterolemia treatment recommendations in the US
12 Figure 2: Hypercholesterolemia treatment recommendations in Europe and Japan
14 Figure 3: Hypercholesterolemia recommendations for specific drug classes
15 Figure 4: Hypertriglyceridemia recommendations for specific drug classes
15 Figure 5: Usage of major drug classes
19 Figure 6: Trends in prevalent cases of dyslipidemia, 2018–27
27 Figure 7: Overview of pipeline drugs for dyslipidemia in the US
27 Figure 8: Pipeline drugs for dyslipidemia, by company
28 Figure 9: Pipeline drugs for dyslipidemia, by drug type
28 Figure 10: Pipeline drugs for dyslipidemia, by classification
36 Figure 11: Probability of success in the dyslipidemia pipeline
37 Figure 12: Licensing and asset acquisition deals in dyslipidemia, 2014–19
40 Figure 13: Clinical trials in dyslipidemia
40 Figure 14: Top 10 drugs for clinical trials in dyslipidemia
41 Figure 15: Top 10 companies for clinical trials in dyslipidemia
41 Figure 16: Trial locations in dyslipidemia
42 Figure 17: Dyslipidemia trials status
43 Figure 18: Dyslipidemia trials sponsors, by phase
45 Figure 19: Datamonitor Healthcare’s drug assessment summary for dyslipidemia
48 Figure 20: Dyslipidemia CVOTs in the statin era
48 Figure 21: Major statin comparison – LDL-C lowering
49 Figure 22: Ezetimibe – LDL-C lowering
49 Figure 23: PCSK9 comparison – LDL-C lowering
50 Figure 24: Inclisiran – LDL-C lowering in Phase III: ASCVD patients (ORION-10, -11) and HeFH (ORION-9)
51 Figure 25: Heterozygous familial hypercholesterolemia comparison – LDL-C lowering
52 Figure 26: Omega-3 FA comparison – triglyceride lowering
53 Figure 27: Fenofibrate – triglyceride lowering
59 Figure 28: Future trends in dyslipidemia
67 Figure 29: Inclisiran for Dyslipidemia (November 16, 2019): Phase III – ORION-10 (US)
67 Figure 30: Inclisiran for Dyslipidemia (November 18, 2019): Phase III – ORION-9 (Heterozygous FH Subjects)
69 Figure 31: Vascepa for Dyslipidemia (Cardiovascular Disease indication; November 18, 2019): Phase II – EVAPORATE
76 Figure 32: ARO-ANG3 for Dyslipidemia and ARO-APOC3 for Lipoprotein Lipase Deficiency (September 16, 2019): Phase I – SAD/MAD (AROAPOC31001)
78 Figure 33: Inclisiran for Dyslipidemia (September 2, 2019): Phase III – ORION-11 (EU)
80 Figure 34: ETC-1002/Ezetimibe FDC for Dyslipidemia (August 29, 2019): Phase II – 1002-058 (T2DM & Elevated LDLCholesterol)
83 Figure 35: Evinacumab for Dyslipidemia (August 14, 2019): Phase III – ELIPSE HoFH
87 Figure 36: Inclisiran for Dyslipidemia (May 18, 2019): Phase II – ORION-3 (OLE)
95 Figure 37: Vascepa for Dyslipidemia (Cardiovascular Disease indication; November 10, 2018): Phase III – REDUCE-IT
96 Figure 38: Key upcoming events in dyslipidemia
LIST OF TABLES
17 Table 1: Prevalent cases of dyslipidemia, 2018–27
21 Table 2: Marketed drugs for dyslipidemia
29 Table 3: Pipeline drugs for dyslipidemia in the US
55 Table 4: Dyslipidemia – hypercholesterolemia segment, current and future market dynamics analysis
57 Table 5: Dyslipidemia – hypertriglyceridemia segment, current and future market dynamics analysis
62 Table 6: Historical global sales, by drug ($m), 2014–18
63 Table 7: Forecasted global sales, by drug ($m), 2019–23
64 Table 8: Inclisiran for Dyslipidemia (November 16 & 18, 2019)
68 Table 9: Vascepa for Dyslipidemia (November 18, 2019)
70 Table 10: Vascepa for Dyslipidemia (November 14, 2019)
72 Table 11: Vascepa for Dyslipidemia (November 12, 2019)
74 Table 12: ARO-ANG3 for Dyslipidemia and ARO-APOC3 for Lipoprotein Lipase Deficiency (September 16, 2019)
77 Table 13: Inclisiran for Dyslipidemia (September 2, 2019)
79 Table 14: ETC-1002/Ezetimibe FDC for Dyslipidemia (August 29, 2019)
81 Table 15: Inclisiran for Dyslipidemia (August 26, 2019)
82 Table 16: Evinacumab for Dyslipidemia (August 14, 2019)
84 Table 17: Vascepa for Dyslipidemia (August 8, 2019)
85 Table 18: Inclisiran for Dyslipidemia (May 18, 2019)
88 Table 19: ETC-1002 for Dyslipidemia (May 5, 2019)
89 Table 20: ETC-1002 for Dyslipidemia (March 13, 2019)
90 Table 21: CER-001 for Dyslipidemia (December 5, 2018)
91 Table 22: Vascepa for Dyslipidemia (November 10, 2018)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
Sign up to the